PMID- 30003393
OWN - NLM
STAT- MEDLINE
DCOM- 20190621
LR  - 20190621
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 172
IP  - 1
DP  - 2018 Nov
TI  - The clinical relevance of serum vascular endothelial growth factor (VEGF) in 
      correlation to circulating tumor cells and other serum biomarkers in patients 
      with metastatic breast cancer.
PG  - 93-104
LID - 10.1007/s10549-018-4882-z [doi]
AB  - PURPOSE: VEGF is one of the most important angiogenesis-stimulating cytokines and 
      has been previously shown to be overexpressed in several solid cancers. The aim 
      of the present study was to assess the clinical relevance of serum VEGF (sVEGF) 
      in a large cohort of metastatic breast cancer patients and to explore the 
      relationship between sVEGF and other blood-based biomarkers. METHODS: Two hundred 
      fifty-three patients with metastatic breast cancer were enrolled in this 
      prospective, multicentre study. Blood samples were collected before start of 
      first-line or later-line treatment. sVEGF was quantified by a commercially 
      available ELISA. Circulating tumor cells (CTCs) were detected using CellSearch 
      and other biomarkers (EGFR, HER2, RAS p21, TIMP1, CAIX) by ELISA. RESULTS: Levels 
      of sVEGF were determined in all patients, with a median concentration of 
      231 pg/ml. After a median follow-up of 19 months, median overall survival (OS) 
      was 10.2 months in patients with sVEGF levels above the upper quartile (i.e. 
      367 pg/ml), while median OS has not been reached in patients with 
      sVEGF < 367 pg/ml (p < 0.001). Median progression-free survival (PFS) was 
      4.8 months for patients with sVEGF >/= 367 pg/ml versus 9.1 months with sVEGF 
      levels < 367 pg/ml (p < 0.001). Patients with sVEGF levels >/= 367 pg/ml and >/= 5 
      CTCs had the shortest OS, while those with sVEGF < 367 pg/ml and non-elevated 
      CTCs had the longest OS. CTCs, grading, line of therapy and RAS p21 were 
      independent predictors of OS. sVEGF, line of therapy and CTCs were independent 
      predictors of PFS in the multivariate analysis. CONCLUSIONS: Metastatic breast 
      cancer patients with elevated levels of sVEGF have significantly worse clinical 
      outcome. This finding supports the biological role of VEGF in breast cancer. 
      TRIAL REGISTRATION: Current Controlled Trials ISRCTN59722891 (DETECT).
FAU - Banys-Paluchowski, Malgorzata
AU  - Banys-Paluchowski M
AUID- ORCID: 0000-0002-2374-9482
AD  - Department of Gynecology and Obstetrics, Marienkrankenhaus Hamburg, Hamburg, 
      Germany.
FAU - Witzel, Isabell
AU  - Witzel I
AD  - Department of Gynecology, University Medical Center Hamburg-Eppendorf, 
      Martinistr. 52, 20246, Hamburg, Germany.
FAU - Riethdorf, Sabine
AU  - Riethdorf S
AD  - Department of Tumour Biology, University Medical Center Hamburg-Eppendorf, 
      Hamburg, Germany.
FAU - Pantel, Klaus
AU  - Pantel K
AD  - Department of Tumour Biology, University Medical Center Hamburg-Eppendorf, 
      Hamburg, Germany.
FAU - Rack, Brigitte
AU  - Rack B
AD  - Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
FAU - Janni, Wolfgang
AU  - Janni W
AD  - Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
FAU - Fasching, Peter A
AU  - Fasching PA
AD  - Department of Gynecology and Obstetrics, University Hospital Erlangen, 
      Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University 
      Erlangen-Nuremberg, Erlangen, Germany.
FAU - Aktas, Bahriye
AU  - Aktas B
AD  - Department of Gynecology, University Hospital Leipzig, Leipzig, Germany.
FAU - Kasimir-Bauer, Sabine
AU  - Kasimir-Bauer S
AD  - Department of Obstetrics and Gynecology, University Hospital Essen, University of 
      Duisburg-Essen, Essen, Germany.
FAU - Hartkopf, Andreas
AU  - Hartkopf A
AD  - Department of Obstetrics and Gynecology, University Hospital Tubingen, University 
      of Tubingen, Tubingen, Germany.
FAU - Solomayer, Erich-Franz
AU  - Solomayer EF
AD  - Department of Gynecology and Obstetrics, Saarland University Hospital, 
      Homburg/Saar, Germany.
FAU - Fehm, Tanja
AU  - Fehm T
AD  - Department of Obstetrics and Gynecology, Heinrich-Heine-University Dusseldorf, 
      Dusseldorf, Germany.
FAU - Muller, Volkmar
AU  - Muller V
AD  - Department of Gynecology, University Medical Center Hamburg-Eppendorf, 
      Martinistr. 52, 20246, Hamburg, Germany. vmueller@uke.de.
LA  - eng
PT  - Journal Article
DEP - 20180712
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Biomarkers)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Biomarkers
MH  - Biomarkers, Tumor
MH  - Breast Neoplasms/*blood/mortality/*pathology
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Neoplastic Cells, Circulating/*pathology
MH  - Prognosis
MH  - Risk Factors
MH  - Vascular Endothelial Growth Factor A/*blood
OTO - NOTNLM
OT  - Biomarker
OT  - Breast cancer
OT  - Circulating tumor cell
OT  - Survival
OT  - VEGF
EDAT- 2018/07/14 06:00
MHDA- 2019/06/22 06:00
CRDT- 2018/07/14 06:00
PHST- 2018/07/03 00:00 [received]
PHST- 2018/07/09 00:00 [accepted]
PHST- 2018/07/14 06:00 [pubmed]
PHST- 2019/06/22 06:00 [medline]
PHST- 2018/07/14 06:00 [entrez]
AID - 10.1007/s10549-018-4882-z [pii]
AID - 10.1007/s10549-018-4882-z [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2018 Nov;172(1):93-104. doi: 10.1007/s10549-018-4882-z. 
      Epub 2018 Jul 12.